Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

In this article

Biogen

plans to advance an experimental drug for Alzheimer's disease to late-stage testing despite disappointing mid-stage trial data, the company said Thursday.

Biogen said its experimental drug that targets tau, a protein associated with the memory-robbing disease, failed to show better responses at higher doses.

Nonetheless, Biogen plans to move it into Phase 3 testing because of signals suggesting the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.